Equities analysts expect that SAGE Therapeutics Inc (NASDAQ:SAGE) will report earnings of ($2.40) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for SAGE Therapeutics’ earnings. The lowest EPS estimate is ($2.68) and the highest is ($2.02). SAGE Therapeutics posted earnings per share of ($1.97) during the same quarter last year, which would indicate a negative year over year growth rate of 21.8%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 1st.
On average, analysts expect that SAGE Therapeutics will report full-year earnings of ($7.37) per share for the current financial year, with EPS estimates ranging from ($9.21) to ($5.24). For the next financial year, analysts expect that the company will report earnings of ($10.42) per share, with EPS estimates ranging from ($20.74) to ($5.06). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for SAGE Therapeutics.
SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.84) by $1.48. The firm had revenue of $90.00 million for the quarter.
NASDAQ SAGE traded down $3.38 during mid-day trading on Monday, reaching $142.63. 349,600 shares of the stock were exchanged, compared to its average volume of 499,493. SAGE Therapeutics has a one year low of $59.57 and a one year high of $195.97. The company has a market capitalization of $6.81 billion, a PE ratio of -20.54 and a beta of 2.90.
A number of large investors have recently bought and sold shares of the business. Flinton Capital Management LLC grew its holdings in shares of SAGE Therapeutics by 1,900.0% during the second quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 646 shares during the last quarter. US Bancorp DE grew its holdings in shares of SAGE Therapeutics by 5,593.3% during the second quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 839 shares during the last quarter. Creative Planning acquired a new position in shares of SAGE Therapeutics during the second quarter valued at about $210,000. Atria Investments LLC acquired a new position in shares of SAGE Therapeutics during the second quarter valued at about $218,000. Finally, Tiverton Asset Management LLC acquired a new position in shares of SAGE Therapeutics during the second quarter valued at about $229,000.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Further Reading: Market Capitalization – What it Means for Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.